Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02946073
Other study ID # HS-16-555
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date September 2016
Est. completion date February 2019

Study information

Verified date January 2021
Source Braeburn Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase III, placebo-controlled, multicenter study with an enriched-enrollment withdrawal (EEW) design to evaluate the efficacy and safety of CAM2038 in opioid-experienced subjects with moderate to severe CLBP that requires continuous, around-the-clock (ATC) opioid treatment ≥ 40 mg morphine equivalent dose (MED). The study includes 5 phases: A Screening Phase (up to 2 weeks), a Transition Phase (up to 2 weeks), an Open-Label Titration Phase (up to 10 weeks), a Double-Blind Treatment Phase including a Final Study Visit (12 weeks), and a Follow-up Phase (4 weeks). The overall duration of participation in the core phase of the study (randomized Double-Blind Phase) is up to 30 weeks, from the Screening Phase through the Follow-up Phase. Subjects who complete the Double-Blind Treatment Study Phase will be offered an opportunity to continue treatment in an open label safety extension for up to 60 weeks. Additional subjects may be recruited to open label safety extension to meet the goal of 100 subjects with 60 weeks of treatment.


Recruitment information / eligibility

Status Completed
Enrollment 1053
Est. completion date February 2019
Est. primary completion date May 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Written informed consent provided prior to the conduct of any study-related procedures. 2. Male or non-pregnant, non-lactating female subject, greater than or equal to 18 years old. 3. Body mass index (BMI) between 18 and 38 kg/m2, inclusive. 4. Treated with daily opioids for moderate to severe CLBP for a minimum of 3 months prior to Screening. 5. On a stable dose of =40 mg/day of oral morphine or MED during the 14 days prior to Screening. 6. Systolic blood pressure =100 mmHg and diastolic blood pressure =60 mmHg. 7. Female subject of childbearing potential who is willing to use a reliable method of contraception during the entire study (Screening Visit to final Follow-up). To be considered not of childbearing potential, female subjects must be surgically sterile (hysterectomy or bilateral oophorectomy, or bilateral tubal ligation with surgery at least 6 weeks before Screening). 8. Male subject who is willing to use reliable contraception 9. Willing and able to comply with all study procedures and requirements. Exclusion Criteria: 1. Positive for hepatitis B surface antigen, hepatitis C viral RNA, or antibodies to human immunodeficiency virus (HIV). 2. Clinically significant symptoms, medical conditions, or other circumstances which, in the opinion of the investigator, would preclude compliance with the protocol, adequate cooperation in the study, or obtaining informed consent, or may prevent the subject from safely participating in the study, including the following: 1. Severe respiratory insufficiency, respiratory depression, airway obstruction, gastrointestinal motility disorders, biliary tract disease, severe hepatic insufficiency, or planned surgery. 2. Bipolar disorder 3. Current diagnosis of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition-defined moderate to severe substance use disorder (including alcohol), other than caffeine or nicotine. 4. Female subject planning to become pregnant during the study. 5. Surgical procedure(s) for CLBP within 6 months prior to Screening. 6. Concomitant disease(s) that could prolong the QTcF interval, such as autonomic neuropathy (caused by diabetes or Parkinson's disease), HIV, cirrhosis, Long QT Syndrome, or family history of Long QT Syndrome. 7. QTcF >450 ms for males and >470 ms for females, or clinically significant electrocardiogram (ECG) abnormality at Screening, at the investigator's discretion. 8. Currently taking medications that have the potential to prolong the QTcF interval or may require such medications during the course of the study (Appendix 1) and has clinically significant abnormalities on screening ECG readings, as determined by the investigator. 9. A nerve or plexus block, including epidural steroid injections or facet blocks, within 1 month prior to Screening or botulinum toxin injection in the lower back region within 3 months of Screening. 10. History of chemotherapy or confirmed malignancy (except basal cell carcinoma) within the past 2 years. 11. Any other acute or chronic pain condition that could interfere with the subject's ability to report their CLBP accurately and consistently and/or interfere with the study staff's ability to assess the subjects CLBP. 12. An active or pending workman's compensation, insurance claim, or litigation related to back pain (i.e., primary claim is back pain). 13. Clinically significant history, in the opinion of the investigator, of suicidal ideation or current evidence that the subject is actively suicidal. 14. Clinically significant history of major depressive disorder that is poorly controlled with medication, per investigator judgment. 15. Hypersensitivity or allergy to BPN, other opioids, or excipients of CAM2038. 16. Hypersensitivity or allergy to acetaminophen. 17. Use of strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4), such as some azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., clarithromycin), or protease inhibitors (e.g., ritonavir, indinavir, and saquinavir) within the 30 days prior to Screening, 18. Use or planned use of natural supplements that can affect CYP3A4, such as St. John's Wort, throughout the study. 19. Has a major bleeding disorder, such as hemophilia, or treated with high levels of anticoagulants per the investigator's discretion. 20. Current or confirmed past diagnosis of Sphincter of Oddi dysfunction. 21. Has a significant hepatic disease, as indicated by Screening clinical laboratory assessment results (aspartate aminotransferase, alanine aminotransferase, or lactate dehydrogenase values =3 × the upper limit of normal [ULN]) or has a creatinine value =1.5 × ULN). 22. Is an employee of the investigator or the trial site, with direct involvement in the proposed trial or other studies under the direction of the investigator or trial site or is a family member of the investigator or of an employee of the investigator. 23. Has any pending legal action that could prohibit participation or compliance in the study. Criteria for Entry into the Titration Phase: 1. After at least a 12-hour washout from the last IR morphine dose, subject must have a COWS =5 and an API pain score over the past 24 hours =5 in order to receive a test dose of Buprenex. 2. Passed all baseline criteria, including a normal QTcF, had no change in QTcF >30 ms at 1 hour after the test dose with Buprenex, and had a COWS score <5 after the test dose with Buprenex. Note: - Subjects on BPN at Screening are required to participate in the down titration and will undergo a washout period prior to the test dose and first on-study treatment. Subjects entering the study on BPN will not transition to IR Morphine, but will refrain from taking their BPN for 12 -24 hours prior to the test dose to achieve the desired washout period. - Subjects on BPN at Screening are still required to follow the same Day 1 procedures (e.g., confirmation of pain scores, COWS assessment and Buprenex test dose) as non-BPN subjects. Criteria for Randomization into the Double-Blind Phase: 1. Been on a stable dose of CAM2038 q1w for at least 2 consecutive weeks. 2. CAM2038 titrated to a dose that provides analgesia (i.e., 7-day API score of =4 and at least 2 points below the value at the start of Titration Phase) and is well tolerated for 7 days before randomization. 3. Requires no more than an average of one hydrocodone/acetaminophen 5 mg/325 mg/day during the last 7 days prior to randomization. 4. Demonstrated study medication (CAM2038) compliance =80% during the previous 14 days. 5. Demonstrated daily compliance with pain intensity scoring for =11 of the previous 14 days, including the last 3 days prior to randomization. Inclusion Criteria for Open Label Extension For Subjects Continuing from The Randomized Double-Blind Phase. Subjects must have: 1. Completed Double Blind Phase of the study 2. Signed Informed Consent for Safety Extension Subjects completing the double-blind phase will be enrolled directly into the open label extension at their respective dose level of CAM2038. They will not be required to participate in a Buprenex treatment test dosing or participate in a titration phase. For De Novo Subjects (New Subjects Recruited Directly into The Open Label Extension) Subjects who are not participating in the Double-Blind Phase of the Study must meet all of the following inclusion criteria in order to be eligible for participation in the study: 1. Written informed consent provided prior to the conduct of any study-related procedures. 2. Male or non-pregnant and non-lactating female subject, greater than or equal to 18 years old. 3. BMI between 18 and 38 kg/m2, inclusive. 4. Treated with daily opioids for moderate to severe chronic pain disorder such as CLBP or osteoarthritis for a minimum of 3 months prior to Screening. 5. On a stable dose of >40 mg/day of oral morphine or MED during the 14 days prior to Screening. 6. Systolic blood pressure =100 mmHg and diastolic blood pressure =60 mmHg. 7. Female subject of childbearing potential who is willing to use a reliable method of contraception during the entire study (Screening Visit to final Follow-up). To be considered not of childbearing potential, female subjects must be surgically sterile (hysterectomy or bilateral oophorectomy, or bilateral tubal ligation with surgery at least 6 weeks before Screening). 8. Male subject who is willing to use reliable contraception 9. Willing and able to comply with all study procedures and requirements. Exclusion Criteria for Subjects Continuing from The Randomized Double-Blind Phase 1. Clinically significant symptoms, medical conditions, or other circumstances which, in the opinion of the investigator, would preclude compliance with the protocol, adequate cooperation in the study, or obtaining informed consent, or may prevent the subject from safely participating in the study. Exclusion Criteria for De Novo Subjects only: Same exclusion criteria as for subjects participating in the Randomized Double-Blind Treatment Phase. Criteria for Entry into the Titration Phase (for De novo subjects): 1. After at least a 12-hour washout from the last IR morphine dose, subject should have a COWS =5 and an API pain score over the past 24 hours =5 in order to receive a test dose of Buprenex. 2. Passed all baseline criteria, including a normal QTcF, had no change in QTcF >30 ms at 1 hour after the test dose with Buprenex, and had a COWS score <5 after the test dose with Buprenex. Note: - Subjects on BPN at Screening are required to participate in the down titration and will undergo a washout period prior to the test dose and first on-study treatment. Subjects entering the study on BPN will not transition to IR Morphine, but will refrain from taking their BPN for 12 -24 hours prior to the test dose to achieve the desired washout period. - However, subjects on BPN at Screening are still required to follow the same Day 1 procedures (e.g., confirmation of pain scores, COWS assessment and Buprenex test dose) as non-BPN subjects. Criteria for Enrolment into the Open Label Treatment Phase (for de Novo subjects): 1. Been on a stable dose of CAM2038 q1w for at least 2 consecutive weeks. 2. CAM2038 titrated to a dose that provides analgesia (i.e., 7-day API score of =4 and at least 2 points below the value at the start of Titration Phase) and is well tolerated for 7 days before randomization. 3. Requires no more than an average of one hydrocodone/acetaminophen 5 mg/325 mg/day during the last 7 days prior to randomization

Study Design


Intervention

Drug:
buprenorphine

Other:
Placebo


Locations

Country Name City State
United States Hassman Research Institute Berlin New Jersey
United States Parkway Medical Center Birmingham Alabama
United States Millennium Pain Center Bloomington Illinois
United States River Birch Research Alliance LLC Blue Ridge Georgia
United States Injury Care Research, LLC Boise Idaho
United States Tampa Pain Relief Center-Brandon Brandon Florida
United States Coastal Carolina Research Center Charleston South Carolina
United States Medical Research South, LLC Charleston South Carolina
United States Aventiv Research, Inc. Columbus Ohio
United States Frost Medical Group, LLC Conshohocken Pennsylvania
United States FutureSearch Trials of Dallas, LP Dallas Texas
United States Renaissance Clinical Research and Hypertension Clinic Dallas Texas
United States Dayton Outpatient Center (DOC) Clinical Research Dayton Ohio
United States Providence Health Partners-Center for Clinical Research Dayton Ohio
United States International Research Partners Doral Florida
United States The SMART Clinic/Physicians Research Options LLC Draper Utah
United States Otrimed Edgewood Kentucky
United States Medisphere Medical Research Center Evansville Indiana
United States Rapha Institute for Clinical Research Fayetteville North Carolina
United States Amicis Trials Festus Missouri
United States MD Studies, Inc. Fountain Valley California
United States Neuro-Pain Medical Center Fresno California
United States Clinical Investigation Specialists, Inc.-Gurnee Gurnee Illinois
United States Boyett Health Services Inc Hamilton Alabama
United States OnSite Clinical Solutions, LLC-Hickory Hickory North Carolina
United States Pioneer Research Solutions Inc. Houston Texas
United States Research Concepts GP, LLC-Houstion Houston Texas
United States Dr. Vijapura and Associates Jacksonville Florida
United States Florida Institute of Medical Research Jacksonville Florida
United States Columbus Regional Research Institute Knoxville Georgia
United States New Phase Research & Development Knoxville Tennessee
United States Alliance Research Centers Laguna Hills California
United States Clinical Trials Research Lincoln California
United States Lake Howell Health Center Maitland Florida
United States Drug Studies America Marietta Georgia
United States Non-Surgical Orthopedics, P.C. Marietta Georgia
United States Suburban Research Associates Media Pennsylvania
United States Ocean Blue Medical Research Center, Inc. Miami Springs Florida
United States Catalina Research Institute, LLC Montclair California
United States EPIC Medical Research Murray Utah
United States MedEx Healthcare Research, Inc-NY New York New York
United States New York Clinical Trials, Inc New York New York
United States Scientific Clinical Research, Inc. North Miami Florida
United States Medical Research Internationl Oklahoma City Oklahoma
United States SP Research, PLLC Oklahoma City Oklahoma
United States Aspen Clinical Research Orem Utah
United States International Clinical Research Institute Inc. Overland Park Kansas
United States Arizona Research Center Phoenix Arizona
United States Elite Clinical Studies Phoenix Arizona
United States Noesis Pharma Phoenix Arizona
United States Phoenix Clinical Phoenix Arizona
United States The Pain Relief Center Plano Texas
United States Gold Coast Research, LLC Plantation Florida
United States Phoenix Medical Research Prairie Village Kansas
United States Mid Columbia Research Richland Washington
United States Allied Clinical Research, LLC Sacramento California
United States FMPM Research Saint Petersburg Florida
United States Care Practice San Francisco California
United States Syrentis Clinical Research Santa Ana California
United States River Cities Clinical Research Center Shreveport Louisiana
United States Clinical Research of West Florida-Tampa Tampa Florida
United States Tampa Pain Relief Centers-Hillsborough Tampa Florida
United States Universal Pain Management Group Valencia California
United States National Centers for Pain Management and Research Vestavia Hills Alabama
United States Boston Paincare Waltham Massachusetts
United States MedVadis Research Corporation Watertown Massachusetts
United States Palm Beach Research Center West Palm Beach Florida
United States Upstate Clinical Research Associates Williamsville New York
United States Center for Clinical Research, LLC-Winston-Salem Winston-Salem North Carolina

Sponsors (3)

Lead Sponsor Collaborator
Braeburn Pharmaceuticals Camurus AB, Medpace, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) and the Primary Timepoint Will be Week 12 of the Double-Blind Phase. Change from baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) and the primary timepoint will be Week 12 of the Double-Blind Phase based on the 11-Point numerical rating scale with 0 being no pain and 10 being the worst pain. 12 weeks- from randomization baseline to 12 weeks after randomization
Primary Change From Baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) of the Open Label Phase. Change from baseline in Weekly Average of (Daily) Average Pain Intensity (WAAPI) of the Open Label Phase based on the 11-Point numerical rating scale with 10 being the worst pain. Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects. 48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).
Secondary Change From Baseline in the Weekly Average of (Daily) Worst Pain Intensity Scores at Week 12 of the Double-Blind Phase Based on 11-Point Numerical Rating Scale With 10 Being the Worst Pain. Change from baseline in Weekly Average of (Daily) Worst Pain Intensity (WAWPI) and the primary timepoint will be Week 12 of the Double-Blind Phase based on the 11-Point numerical rating scale with 0 being no pain and 10 being the worst pain. 12 weeks- from randomization baseline to 12 weeks after randomization
Secondary Number of Subjects With a 30% and 50% Reduction in WAAPI From Baseline to Week 12 of the Double-Blind Phase. Number of Responders With a 30% and 50% Reduction in WAAPI from the Open-Label Titration Period Baseline to Week 12 of the Double-Blind Treatment Period (mITT Population) 12 weeks- from randomization baseline to 12 weeks after randomization
Secondary Summary of Rescue Medication Usage- Double-Blind Phase. Rescue medication usage (number of days used) during the Double-Blind Phase. 12 weeks- from randomization baseline to 12 weeks after randomization
Secondary Change From Open Label Titration Baseline to Week 12 of the Double-Blind Phase in EuroQol Group 5-dimension 5-level Self-report Questionnaire Score. Change from Open Label Titration baseline to Week 12 of the Double-Blind Phase in EuroQol Group 5-dimension 5-level self-report questionnaire score. The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) descriptive system is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows subjects to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood, using a 5-level scale. These combinations of attributes were converted into a weighted health-state index score, according to the US population-based algorithm, with higher scores indicating better quality of life. The score ranges from 0-100 with 0 as the worst health and 100 as the best health. 12 weeks- from randomization baseline to 12 weeks after randomization
Secondary Change From Baseline to Week 12 of the Double-Blind Phase in Work Productivity and Activity Impairment Score Change from baseline to Week 12 of the Double-Blind Phase in Work Productivity and Activity Impairment score. The Work Productivity and Activity Impairment (WPAI) is a self-administered instrument used to measure the effect of general health and symptom severity on work productivity and regular activities, and yields 4 types of scores (higher scores indicate greater impairment): Absenteeism (work time missed),Presenteeism (impairment at work/reduced on-the-job effectiveness), Work Productivity Loss (overall work impairment/absenteeism plus presenteeism),and Activity Impairment. Scores range from 0-100 for each of the four types with higher scores indicating greater impairment. 23 weeks- from baseline to 12 weeks after randomization
Secondary Number of Subjects Discontinued Due to Loss of Efficacy Number of Subjects Discontinued due to loss of efficacy, defined as discontinuation of study drug for lack of efficacy. 12 weeks- from randomization baseline to 12 weeks after randomization
Secondary Change From Baseline to Week 12 of the Double-Blind Phase in Patient Global Impression of Improvement (PGI-I) Scale Change from baseline to Week 12 of the Double-Blind Phase in Patient global Impression of Improvement (PGI-I) Scale. PGI-I)Scale is a single question 7-point likert scale that required the subject to assess how much his/her pain had improved or worsened relative to the start of the study at the beginning of the intervention . Ratings were: 1, much worse; 2, worse; 3, a little worse; 4, no change; 5, a little better; 6, better; or 7, much better 12 weeks- from baseline (randomization) to 12 weeks after randomization
Secondary Change From Baseline in Weekly Average of (Daily) Worst Pain Intensity (WAWPI) of the Open Label Phase. Change from baseline in Weekly Average of (Daily) Worst Pain Intensity (WAWPI) and the primary timepoint will be Week 52 of the Open Label Phase based on the 11-Point numerical rating scale with 10 being the worst pain. Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects. 48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).
Secondary Subject Discontinued Due to Loss of Efficacy, Defined as Discontinuation of Study Drug for Lack of Efficacy. Subject Discontinued Due to Loss of Efficacy, Defined as Discontinuation of Study Drug for Lack of Efficacy Open Label Phase. 48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).
Secondary Summary of Rescue Medication Usage-Open Label Phase Rescue medication usage (number of days used) during the Open Label Phase. 48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).
Secondary Summary of Change From Baseline in EuroQoL Group EQ-5D-5L Scores Over Time-Open Label Phase Change from Open Label Titration baseline in EuroQol Group 5-dimension 5-level self-report questionnaire score in the Open Label Phase. The EuroQoL Group 5-Dimension 5-Level Self-Report Questionnaire (EQ-5D-5L) descriptive system is a generic, multidimensional, health-related, quality-of-life instrument. The profile allows subjects to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood, using a 5-level scale. These combinations of attributes were converted into a weighted health-state index score, according to the US population-based algorithm, with higher scores indicating better quality of life. The score ranges from 0-100 with 0 as the worst health and 100 as the best health. 48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).
Secondary Summary of Change From Baseline in Clinical Global Impression of Improvement (CGI-I) Scale-Open Label Summary of Change from Baseline in Clinical Global Impression of Improvement (CGI-I) scale. The Clinician Global Impression of Improvement (CGI-I) Scale is a 7-point scale that required the clinician to assess how much the subject's Pain had improved or worsened relative to the start of the study. Assessments were rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse 48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).
Secondary Summary of Change From Baseline in Patient Global Impression of Improvement (PGI-I) Scale Change from baseline in the Open Label Phase in Patient global Impression of Improvement (PGI-I) Scale. PGI-I Scale is a single question 7-point likert scale that required the subject to assess how much his/her pain had improved or worsened relative to the start of the study. Ratings were: 1, much worse; 2, worse; 3, a little worse; 4, no change; 5, a little better; 6, better; or 7, much better 48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).
Secondary Summary of Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Open Label Phase Change from baseline in the Open Label Phase in Work Productivity and Activity Impairment score with a range of 0-100 for 4 types of scores with higher scores indicating greater impairment. The Work Productivity and Activity Impairment (WPAI) is a self-administered instrument used to measure the effect of general health and symptom severity on work productivity and regular activities, and yields 4 types of scores (higher scores indicate greater impairment): Absenteeism (work time missed),Presenteeism (impairment at work/reduced on-the-job effectiveness), Work Productivity Loss (overall work impairment/absenteeism plus presenteeism),and Activity Impairment. Scores range from 0-100 for each of the four types with higher scores indicating greater impairment. 48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).
Secondary Number of Subjects Discontinued Due to Loss of Efficacy Number of Subjects Discontinued due to loss of efficacy, defined as discontinuation of study drug for lack of efficacy. 48 weeks -From baseline to 48 weeks after baseline (Baseline is defined as the last week prior to Visit 14 (Randomization Visit) for the roll-over subjects and the last week prior to Visit 14 (Enrollment Visit) for de novo subjects).
See also
  Status Clinical Trial Phase
Completed NCT01659073 - Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation N/A
Recruiting NCT05914311 - Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration N/A
Recruiting NCT05422456 - The Turkish Version of Functional Disability Inventory
Enrolling by invitation NCT05422443 - The Turkish Version of Pain Coping Questionnaire
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04385030 - Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury N/A
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05103319 - Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
Completed NCT03687762 - Back on Track to Healthy Living Study N/A
Completed NCT04171336 - Animal-assisted Therapy for Children and Adolescents With Chronic Pain N/A
Completed NCT03179475 - Targin® for Chronic Pain Management in Patients With Spinal Cord Injury Phase 4
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Recruiting NCT06060028 - The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain N/A
Recruiting NCT06204627 - TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT00983385 - Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics Phase 3
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Not yet recruiting NCT05812703 - Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain